Unknown

Dataset Information

0

Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data.


ABSTRACT: : To treat hypertension, combining two or more antihypertensive drugs from different classes is often necessary. β-Blockers and renin-angiotensin-aldosterone system inhibitors, when combined, have been deemed 'less effective' based on partially overlapping mechanisms of action and limited evidence. Recently, the single-pill combination (SPC) of nebivolol (Neb) 5 mg - a vasodilatory β1-selective antagonist/β3 agonist - and valsartan 80 mg, an angiotensin II receptor blocker, was US Food and Drug Administration-approved for hypertension. Pharmacological profiles of Neb and valsartan, alone and combined, are well characterized. In addition, a large 8-week randomized trial in stages I-II hypertensive patients (N = 4161) demonstrated greater blood pressure-reducing efficacy for Neb/valsartan SPCs than component monotherapies with comparable tolerability. In a biomarkers substudy (N = 805), Neb/valsartan SPCs prevented valsartan-induced increases in plasma renin, and a greater reduction in plasma aldosterone was observed with the highest SPC dose vs. valsartan 320 mg/day. This review summarizes preclinical and clinical evidence supporting Neb/valsartan as an efficacious and well tolerated combination treatment for hypertension.

SUBMITTER: Giles TD 

PROVIDER: S-EPMC5548499 | biostudies-other | 2017 Sep

REPOSITORIES: biostudies-other

Similar Datasets

| S-EPMC5484387 | biostudies-literature
| S-EPMC4251532 | biostudies-literature
| S-EPMC5813198 | biostudies-literature
| S-EPMC4585112 | biostudies-literature
| S-EPMC7213059 | biostudies-literature
| S-EPMC3622365 | biostudies-literature
| S-EPMC6312595 | biostudies-literature
| S-EPMC7526577 | biostudies-literature
| S-EPMC5685772 | biostudies-literature
| S-EPMC10478086 | biostudies-literature